Rigel Pharmaceuticals Inc. (New)
RIGLStock
$41.67+117.88%52W
Market Cap$758.22M
P/E2.07x
Div yield—
Beta1.18
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.90%
Price vs S&P 500 (4W)26.27%
VGM Score69.62
Market Capitalization$758.22M
P/E Ratio (Annual)2.07x
Earnings Surprise History
Q1 260.44est. 0.70
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.09
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RIGLRigel Pharmaceuticals Inc. (New) | B | B | B | $41.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Rigel Pharmaceuticals develops small-molecule therapeutics for autoimmune, cancer, and viral diseases. The company markets TAVALISSE, an oral SYK inhibitor, and generates revenue through a partnership with AstraZeneca for an oral rheumatoid arthritis candidate, earning royalties and milestone payments. Its pipeline includes additional candidates targeting SYK and JAK pathways.